A detailed history of Prelude Capital Management, LLC transactions in Harrow Health, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 26,958 shares of HROW stock, worth $945,686. This represents 0.08% of its overall portfolio holdings.

Number of Shares
26,958
Previous 26,958 -0.0%
Holding current value
$945,686
Previous $1.21 Million -0.0%
% of portfolio
0.08%
Previous 0.05%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$20.85 - $46.47 $1.63 Million - $3.64 Million
-78,251 Reduced 74.38%
26,958 $1.21 Million
Q2 2024

Aug 14, 2024

SELL
$10.0 - $21.64 $49,500 - $107,118
-4,950 Reduced 4.49%
105,209 $2.2 Million
Q1 2024

May 15, 2024

BUY
$9.3 - $13.23 $161,913 - $230,334
17,410 Added 18.77%
110,159 $1.46 Million
Q4 2023

Feb 14, 2024

BUY
$8.1 - $16.36 $24,364 - $49,210
3,008 Added 3.35%
92,749 $1.04 Million
Q3 2023

Nov 14, 2023

BUY
$14.03 - $22.08 $607,288 - $955,732
43,285 Added 93.17%
89,741 $1.29 Million
Q2 2023

Aug 14, 2023

BUY
$17.37 - $28.08 $47,819 - $77,304
2,753 Added 6.3%
46,456 $884,000
Q1 2023

May 15, 2023

SELL
$13.84 - $21.46 $833,389 - $1.29 Million
-60,216 Reduced 57.95%
43,703 $924,000
Q4 2022

Feb 14, 2023

BUY
$10.28 - $14.78 $193,551 - $278,277
18,828 Added 22.13%
103,919 $1.53 Million
Q3 2022

Nov 14, 2022

SELL
$6.57 - $24.88 $83,622 - $316,672
-12,728 Reduced 13.01%
85,091 $1.03 Million
Q2 2022

Aug 15, 2022

BUY
$5.75 - $7.74 $16,721 - $22,507
2,908 Added 3.06%
97,819 $712,000
Q1 2022

May 16, 2022

BUY
$6.77 - $8.66 $164,463 - $210,377
24,293 Added 34.4%
94,911 $647,000
Q4 2021

Feb 14, 2022

BUY
$8.5 - $12.0 $71,578 - $101,052
8,421 Added 13.54%
70,618 $610,000
Q3 2021

Nov 15, 2021

BUY
$6.99 - $10.6 $59,268 - $89,877
8,479 Added 15.78%
62,197 $565,000
Q2 2021

Aug 16, 2021

BUY
$6.68 - $11.07 $139,404 - $231,019
20,869 Added 63.53%
53,718 $499,000
Q1 2021

May 17, 2021

SELL
$6.26 - $11.03 $773,848 - $1.36 Million
-123,618 Reduced 79.01%
32,849 $222,000
Q4 2020

Feb 16, 2021

BUY
$4.76 - $6.93 $12,490 - $18,184
2,624 Added 1.71%
156,467 $1.07 Million
Q3 2020

Nov 16, 2020

SELL
$4.71 - $7.36 $197,975 - $309,362
-42,033 Reduced 21.46%
153,843 $860,000
Q2 2020

Aug 14, 2020

SELL
$3.61 - $6.47 $394,836 - $707,643
-109,373 Reduced 35.83%
195,876 $1.02 Million
Q1 2020

May 15, 2020

BUY
$3.5 - $7.31 $543,599 - $1.14 Million
155,314 Added 103.59%
305,249 $1.17 Million
Q4 2019

Feb 14, 2020

SELL
$4.6 - $7.88 $323,844 - $554,759
-70,401 Reduced 31.95%
149,935 $1.17 Million
Q3 2019

Nov 14, 2019

BUY
$4.89 - $8.0 $489,665 - $801,088
100,136 Added 83.31%
220,336 $1.24 Million
Q2 2019

Aug 14, 2019

SELL
$4.2 - $8.7 $198,227 - $410,613
-47,197 Reduced 28.19%
120,200 $1.05 Million
Q1 2019

May 15, 2019

BUY
$4.75 - $7.1 $795,135 - $1.19 Million
167,397 New
167,397 $834,000

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $950M
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.